Emergent BioSolutions announced FDA approval for new 6-count and 24-count multipack configurations of NARCAN® Nasal Spray, designed to improve distribution efficiency and accessibility for high-volume partners. The new formats will be available through NARCANDirect® and complement recent approval of a NARCAN® carrying case, supporting the company's efforts to combat opioid overdose deaths.

The global lipid nanoparticle (LNP) manufacturing market is valued at USD 565 million in 2026 and is expected to reach USD 2.24 trillion by 2034, growing at an 18.9% CAGR. North America currently dominates the market, while Asia-Pacific is experiencing notable expansion. Key growth drivers include mRNA vaccine development, precision medicine demand, and gene therapy applications. Solid lipid nanoparticles and nucleic acids segments lead current market share, while nanostructured lipid carriers and small molecules segments are expected to grow rapidly.

The global biodefense market is projected to grow from USD 16.81 billion in 2024 to USD 32.87 billion by 2034, driven by advancements in biotechnology, increased government funding, and growing awareness of biological threats.

Emergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.

Emergent BioSolutions and Rocketvax have announced a strategic partnership, where Emergent will invest in Rocketvax and lead the U.S. manufacturing and commercialization of four of Rocketvax's pipeline candidates for infectious diseases, cancer, and autoimmune disorders.

The global vaccine contract manufacturing market is expected to grow significantly, driven by rising demand for immunization and the need for agile and scalable vaccine production, particularly in response to emerging infectious diseases.

Africa CDC is leading the MOSA trial, a pan-African randomized platform adaptive trial for the MpOx Study, to evaluate different antivirals for treating the Mpox health threat. The trial is sponsored by PANTHER and initially funded by the European Union's Horizon Europe program.

Emergent BioSolutions stock surged nearly 12% after an analyst at H.C. Wainwright initiated coverage with a buy recommendation and a $15 price target, citing the company's diversified offerings and growth potential in its Narcan opioid reversal spray and vaccines business.

The UN High Commissioner for Human Rights, Volker Türk, has declared that the global war on drugs has failed and called for the international community to abandon punitive drug policies in favor of evidence-based, human rights-focused approaches that prioritize health and inclusion over criminalization.

Emergent BioSolutions' shares fell nearly 6% after the company disclosed that several institutional shareholders are selling their shares and warrants. The selling is not dilutive for Emergent, but investors are wary of the potential impact on the company's future.

Pomerantz LLP announces a proposed class action settlement of $40 million on behalf of purchasers of Emergent BioSolutions Inc. common stock between March 10, 2020 and November 4, 2021. The settlement is subject to court approval.

The global lipid nanoparticles market is expected to grow at a CAGR of 5.2% from 2024 to 2029, driven by the increasing use of lipid nanoparticles in anti-cancer therapies and RNA-based therapies, as well as growing government focus on R&D for lipid nanoparticle-based drugs.